These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 6959488)
61. Haloperidol. Med Lett Drugs Ther; 1967 Sep; 9(18):70-1. PubMed ID: 5233811 [No Abstract] [Full Text] [Related]
62. Family data support a dominant major gene for Tourette syndrome. Price RA; Pauls DL; Kruger SD; Caine ED Psychiatry Res; 1988 Jun; 24(3):251-61. PubMed ID: 3165533 [TBL] [Abstract][Full Text] [Related]
63. Cholinergic and dopaminergic mechanisms in Tourette syndrome. Stahl SM; Berger PA Adv Neurol; 1982; 35():141-50. PubMed ID: 6959486 [No Abstract] [Full Text] [Related]
65. Some uses of haloperidol in the treatment of psychiatric conditions. Abuzzahab FS Psychosomatics; 1970; 11(3):188-93. PubMed ID: 5269397 [No Abstract] [Full Text] [Related]
67. Physostigmine in Tourette syndrome: evidence for cholinergic underactivity. Stahl SM; Berger PA Am J Psychiatry; 1981 Feb; 138(2):240-2. PubMed ID: 6935977 [No Abstract] [Full Text] [Related]
68. Nifedipine augments haloperidol in the treatment of Tourette syndrome. Alessi NE; Walden ME; Hsieh PS Pediatr Neurol; 1988; 4(3):191. PubMed ID: 3242522 [No Abstract] [Full Text] [Related]
69. Assessment of dopaminergic function in children and adults: long and brief debrisoquin administration combined with plasma homovanillic acid. Riddle MA; Leckman JF; Anderson GM; Hardin MT; Ort SI; Towbin KE; Shaywitz BA; Cohen DJ Psychopharmacol Bull; 1987; 23(3):411-4. PubMed ID: 3481088 [No Abstract] [Full Text] [Related]
70. The neurophysiology of Tourette syndrome. Obeso JA; Rothwell JC; Marsden CD Adv Neurol; 1982; 35():105-14. PubMed ID: 6959483 [No Abstract] [Full Text] [Related]
71. PET studies on the integrity of the pre and postsynaptic dopaminergic system in Tourette syndrome. Brooks DJ; Turjanski N; Sawle GV; Playford ED; Lees AJ Adv Neurol; 1992; 58():227-31. PubMed ID: 1414627 [No Abstract] [Full Text] [Related]
72. A "therapeutic window" for haloperidol? Miller DD; Hershey LA J Clin Psychopharmacol; 1986 Aug; 6(4):250-1. PubMed ID: 3734149 [No Abstract] [Full Text] [Related]
73. Variable dose studies provide misleading therapeutic windows. Van Putten T; Marder SR J Clin Psychopharmacol; 1986 Aug; 6(4):249-50. PubMed ID: 3734148 [No Abstract] [Full Text] [Related]
74. A Developmental Perspective of Dopaminergic Dysfunction in Tourette Syndrome. Dwyer JB Biol Psychiatry; 2018 Sep; 84(5):e33-e35. PubMed ID: 30115244 [No Abstract] [Full Text] [Related]
75. Association of a Variant of Szejko N; Fichna JP; Safranow K; Dziuba T; Żekanowski C; Janik P Front Genet; 2020; 11():125. PubMed ID: 32194619 [TBL] [Abstract][Full Text] [Related]
76. Serotonin transporter binding is increased in Tourette syndrome with Obsessive Compulsive Disorder. Müller-Vahl KR; Szejko N; Wilke F; Jakubovski E; Geworski L; Bengel F; Berding G Sci Rep; 2019 Jan; 9(1):972. PubMed ID: 30700759 [TBL] [Abstract][Full Text] [Related]
77. Merging the Pathophysiology and Pharmacotherapy of Tics. Augustine F; Singer HS Tremor Other Hyperkinet Mov (N Y); 2018; 8():595. PubMed ID: 30643668 [TBL] [Abstract][Full Text] [Related]
78. Animal models of tic disorders: a translational perspective. Godar SC; Mosher LJ; Di Giovanni G; Bortolato M J Neurosci Methods; 2014 Dec; 238():54-69. PubMed ID: 25244952 [TBL] [Abstract][Full Text] [Related]
79. Neurobiology of tourette syndrome: current status and need for further investigation. Felling RJ; Singer HS J Neurosci; 2011 Aug; 31(35):12387-95. PubMed ID: 21880899 [TBL] [Abstract][Full Text] [Related]
80. The biochemistry of Tourette's syndrome. Chokka PR; Baker GB; Bornstein RA; de Groot CM Metab Brain Dis; 1995 Jun; 10(2):107-24. PubMed ID: 7675010 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]